Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06353984

Effects of In-between Meal Products on Cognitive Function in the Elderly

The overall aim of the present 9-week intervention study is to determine how a healthy drinkable in between meal affects cognitive function and brain activity in healthy adults 70 years and older. Secondary, the study also investigates the impact of the intervention on low grade inflammation, immune function, gut health, body composition, physical function, and well-being as secondary or exploratory outcomes. The study products have the potential to lower chronic low-grade inflammation in the elderly, improve nutrition and thereby contribute to healthy aging including cognitive function, and the study will also give additional insight regarding secondary and exploratory outcomes.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Age range

70 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Örebro University

Örebro, Sweden

About this study

The current study is a nine week three-arm randomized controlled trial that includes a double-blinded, two-armed intervention and a non-blinded comparative arm without any intervention. This study will investigate the effects of a healthy in between meal consisting of processed oats and chickpeas on cognitive function and functional brain activity in healthy older men and women 70 years and older (primary endpoints) and explore the effect of the intervention product on blood markers, body composition, physical activity, physical function, and self-reported well-being in the earlier mentioned population (secondary endpoint). Furthermore, the study will give insight in the preventative value of the intervention product on earlier mentioned age-related conditions as well as adherence to the study product and gives guidance towards further research regarding the effect of food product on age related conditions. Participants will visit the study centre at seven occasions, one time before (pre visit) and six times during the study period to perform one or more tests and/or examinations. The pre visit takes place before the baseline, visit 1 and 2 are at baseline, and visit 3 and 4 are the mid-study-visits in week 3 and 6 of the interventional period. Visit 5 and 6 take place at the last interventional week, ie week 9. Data and sample collection takes place as following:

  • visit 0: Eligibility screening and informed consent
  • Week 1: visit 1 baseline: Body composition, blood samples, fecal samples, questionnaires and physical activity and function, cognitive function
  • Week 1: visit 2 baseline fMRI: Structural MRI, RS-(MRI), N-back task fMRI, word recognition task
  • Week 3: visit 3 intermediate visit I: Body composition, blood samples, questionnaires, compliance
  • Week 6: visit 4 Intermediate visit I: Body composition, blood samples, questionnaires, compliance
  • Week 9: visit 5 study end: same procedure as visit 1
  • Week 9. Visit 6 study end: same procedure as visit 2

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed informed consent prior to any study-related procedure
  • Age 70 years and above
  • Normal weight to overweight at the screening defined as BMI range 18.5-31.9
  • Willing to abstain from regular consumption of medication known to alter gastrointestinal function or inflammatory status after being included and during the study
  • Willingness to pick up study products and eat the products according to the instructions each day

Exclusion criteria

  • Diagnosis of type 1 and/or type 2 diabetes
  • Immobile (defined as the inability to participate in all study-related procedures)
  • History of complicated gastrointestinal surgery
  • Diagnosed inflammatory bowel disease (IBD)
  • Current diagnosis of psychiatric disease/s or syndromes
  • Current diagnosis of neurodegenerative disease
  • Systemic use of antibiotics and/or steroid medication in the last 4 months prior to inclusion
  • Use of probiotics, prebiotics, fermented foods, kombucha, and any other product known to modulate gut microbiota composition in the last 2 months prior to inclusion
  • Use of any non-steroidal anti-inflammatory drug (NSAID) more than 3 times a week in the last 2 months prior to inclusion
  • Use of statins
  • Consumption of any NSAID within 7 days of study start
  • Any condition which could interfere with intestinal barrier function (e.g. gluten sensitivity, lactose intolerance, celiac disease, IBS, IBD) as decided by the principal investigators' discretion
  • Vegetarian diet
  • Allergy to ingredients included in either investigational or reference products
  • Regular smoking, use of snuff, nicotine, or e-cigarette use
  • Drinking more than 9 standard cups of alcohol per week and/or more than 3 standard cups of alcohol per occasion
  • Regular use, for more than three times a week for the last 2 months and/or 7 days prior to inclusion, of medications which according to the principal investigator can have an anti-inflammatory effect or affect in any way the intestinal barrier function or have an impact on the study analysis (such as laxatives, anti-diarrheal, anti-cholinergic, etc.)
  • After being included in the study, starting any medication or treatment that could potentially influence the study participation and/or study analysis
  • Cerebral bleeding or history of cerebral bleeding
  • Claustrophobia
  • In operated apparatus (e.g., pacemaker)
  • Aneurysm clips or shunts in the head
  • Grenade-splinter or metal-splinter in the body (e.g., eyes)
  • Metal or electrodes in the body (e.g., temp-catheter, aorta stent, cochlea implant)
  • Comprehensive tooth-implants or prosthesis
  • Operated in the head or in the heart
  • Swallowed a video-capsule
  • Left-handed
  • Severe vision impairments
  • Being highly physically active, competing as a master athlete and/or partaking in physical demanding training more than four times per week, extreme exercising
  • Any other reason the investigator feels the subject is not suitable for participation in this aspect of the study

Treatment and study plan

Minimeal product

Dietary Supplement

Intervention product consisting of bioprocessed oats and chickpeas

Reference product

Dietary Supplement

Reference product mimicking available soups and fruit drinks

Primary outcomes

  1. Functional brain activity

    Time frame: 9 weeks

    Functional brain activity will be measured by functional magnetic resonance imaging (fMRI)) during the n-back task

Secondary outcomes

  1. Fasting blood glucose/insulin

    Time frame: 9 weeks

    Fasting blood glucose insulin will be taken and the HOMA index (Homeostatic Model Assessment for Insulin Resistance) expressed in mmol/L or mg/dL will be used to assess insulin resistance

  2. Blood fats/lipid status

    Time frame: 9 weeks

    Blood fats/lipid status unit of measurement concentration given mmol/L

  3. Interleukin-6

    Time frame: 9 weeks

    Concentration of interleukin-6 measured in in blood serum corrected for baseline, unit of measurement concentration given as pg/mL

  4. High-sensitivity C-reactive protein

    Time frame: 9 weeks

    High-sensitivity C-reactive protein (HsCRP) measured in blood corrected for baseline, unit of measurement concentration given as mg/L

  5. Tumor necrosis factor

    Time frame: 9 weeks

    Concentration of Tumor necrosis factor (TNF) in blood serum corrected for baseline, unit of measurement concentration given as pg/mL

  6. Interferon-gamma

    Time frame: 9 weeks

    Concentration of Interferon-gamma (IFN-Gamma) in blood serum corrected for baseline, unit of measurement concentration given as pg/mL

  7. Zonulin

    Time frame: 9 weeks

    Zonulin (haptoglobin 2 precursor) is a protein that increases the permeability of tight junctions between cells of the wall of the digestive tract, measured in faeces.

  8. Intestinal fatty-acid binding protein

    Time frame: 9 weeks

    Intestinal fatty-acid binding protein (I-FABP) measured in faeces

  9. Cognitive function

    Time frame: 9 weeks

    Cognitive function will be assessed by an off-line multi-domain cognitive test battery computer-based, word recognition task

  10. Magnetic resonance imaging (MRI)

    Time frame: 9 weeks

    Resting state connectivity functional MRI (rsfMRI) and brain morphology from structural scans (brain and brain stem) are measured by MRI

  11. The Perceived Stress Scale

    Time frame: 9 weeks

    The Perceived Stress Scale (PSS) questionnaire is used to measure the perception of stress in life and has 10 questions with the following options to answer: 0 = Never 1 = Almost Never 2 = Sometimes 3 = Fairly Often 4 = Very Often

  12. Hospital Anxiety and Depression Scale

    Time frame: 9 weeks

    The validated Hospital Anxiety and Depression Scale (HADS) questionnaire will be used to assesses symptoms of depression and anxiety. The HADS has 7 questions related to depressions and 7 questions related to anxiety. A higher total score indicates more depression or anxiety with the following cut off scores: 0-7 = Normal 8-10 = Borderline abnormal (borderline case) 11-21 = Abnormal (case)

  13. SF 36

    Time frame: 9 weeks

    The SF 36 (short form) questionnaire is used to assess general health Status. The SF-36 consists of 36 questions. Scores for the different domains are converted and pooled using a scoring key, for a total score indicating a range of low to high quality of life

  14. Western Ontario and McMaster Osteoarthritis Index

    Time frame: 9 weeks

    To evaluate hip and knee osteoarthritis Western Ontario and McMaster Osteoarthritis Index (WOMAC) questionnaire is used. The WOMAC is a self-administered questionnaire consisting of 24 items divided into 3 subscales. The test questions are scored on a scale of 0-4, which correspond to: None (0), Mild (1), Moderate (2), Severe (3), and Extreme (4). The scores for each subscale are summed up, with a possible score range of 0-20 for Pain, 0-8 for Stiffness, and 0-68 for Physical Function. A sum of the scores for all three subscales gives a total score

  15. Clinical Outcomes in Routine Evaluation

    Time frame: 9 weeks

    The translated and validated Swedish version of the Clinical Outcomes in Routine Evaluation (CORE-GP) is used to evaluate psychological wellbeing. The CORE-GP consists of 34 questions about how they have been feeling over the last week, using a 5-point scale (not at all, only occasionally, sometimes, often, most or all the time. The scale covers four dimensions: subjective well-being, problems/symptoms, life functioning, risk/harm

  16. Gastrointestinal Symptoms Rating Scale

    Time frame: 9 weeks

    To assess gastrointestinal symptoms the Gastrointestinal Symptoms Rating Scale (GSRS) questionnaire is used. The questionnaire consists of 15 questions combined into five symptom clusters: reflux, abdominal pain, indigestion, diarrhoea and constipation. Each questions is rated on a 7-point likert scale where 1 represents absence of troublesome symptoms and 7 represents very troublesome symptoms

  17. Pittsburgh Sleep Quality Index

    Time frame: 9 weeks

    To assess sleep quality and sleep disturbances over a one-month time interval the Pittsburgh Sleep Quality Index (PSQI) questionnaire is used. Each questionnaire's 19 self reported items belong to one of seven categories: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, daytime dysfunction. The questionnaire consists of a combination of likert-type and open-ended questions. Scores for each question range from 0 to 3, with higher scores indicating more acute sleep disturbances.

  18. International Physical Activity Questionnaire for the Elderly short form

    Time frame: 9 weeks

    The International Physical Activity Questionnaire for the Elderly (IPAQ-E) short form consists of 4 questions regarding time spend sitting, walking, heavy physical activities or sport or very heavy activities or sport

  19. Historical Physical Activity Questionnaire

    Time frame: 9 weeks

    The Historical Physical Activity Questionnaire HAPAQ assesses physical activity behaviour between the age of 20 to 65 years and consists of questions regarding physical activity, sports and labour performed per year, month and average minutes per week

  20. Food frequency questionnaire

    Time frame: 9 weeks

    The Meal-Q Food frequency questionnaire is used to assess if participants have altered dietary patterns during the intervention. The questionnaire consists of 174 questions about foods, dishes and drinks (including alcoholic drinks) as well as pictures of different portion sizes for cooked dishes, questions about meal order, eating behaviour (with regard to restaurant visits, fast food, salad buffets, salt on food, consumption of diet products) and supplements.

  21. Physical activity

    Time frame: Only at baseline (week 1)

    Habitual physical activity will be assessed by accelerometery activity monitor during a week during waking time. Counts per minute are registered and converted into daily average times spent in sedentary behaviour, light-intensity physical activity, and moderate-to-vigorous intensity physical activity.

  22. Muscle mass

    Time frame: 9 weeks

    Muscle mass is assessed with bioelectrical impedance (BIA)

  23. Fat mass

    Time frame: 9 weeks

    Fat mass is assessed with bioelectrical impedance (BIA)

  24. Body mass index

    Time frame: 9 weeks

    Body mass index (BMI) is calculated as weight (in kg)/ height^2 (in m^2)

  25. Waist circumference

    Time frame: 9 weeks

    Waist circumference is measured to the nearest 0.1 cm with a steel tape at the midpoint between iliac crest and lower costal marginBody mass index (BMI)

  26. Aerobic capacity

    Time frame: 9 weeks

    Aerobic capacity is assessed by a maximal walk test on a graded treadmill (Modified Bruce Protocol) where a further stage and time into the stage indicates a better aerobic fitness

  27. Balance

    Time frame: 9 weeks

    Balance by the single leg stance balance test with eyes open and eyes closed where longer time indicates a better balance

  28. 30-sec repeated chair raise

    Time frame: 9 weeks

    Lower body muscle performance is assessed by the 30-sec repeated chair raise where more repetitions indicates a better performance

  29. Maximal leg strength

    Time frame: 9 weeks

    Maximal leg strength is assessed by the leg press exercise where a larger amount in kilograms lifted indicates a higher maximal leg strength

  30. Maximal handgrip strength

    Time frame: 9 weeks

    Maximal handgrip strength by the handgrip test where total amount of kilogram or kilogram per bodyweight indicates a higher total, or relative handgrip strength respectively

Sponsors and collaborators

Lead sponsor

Örebro University, Sweden

Other

Registry information

Official study title

Effects of a Nutritionally Balanced In-between Meal Food Product on Cognitive Function in the Elderly - an Explorative Study

Acronym: Minimeal

Important dates

Study start
2024
Primary completion
2027
Study completion
2027
First posted
Apr 9, 2024
Registry last updated
Feb 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.